We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

4 hedge funds and large institutions have $231K invested in Hepion Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more capital invested

Capital invested by funds: $99K → $231K (+$132K)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$347K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$112K
3
Renaissance Technologies
Renaissance Technologies
New York
+$102K

Top Sellers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
-$23K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$23K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$14K
4
CS
Credit Suisse
Switzerland
-$5K
5
Northern Trust
Northern Trust
Illinois
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$140K +$347K +34 New
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$44K +$112K +11 New
Renaissance Technologies
3
Renaissance Technologies
New York
$43K +$102K +10 New
Barclays
4
Barclays
United Kingdom
$3K – – –
Morgan Stanley
5
Morgan Stanley
New York
$1K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
– -$14K -1 Closed
HighTower Advisors
7
HighTower Advisors
Illinois
– -$23K -1 Closed
Vanguard Group
8
Vanguard Group
Pennsylvania
– -$23K -1 Closed
CS
9
Credit Suisse
Switzerland
– -$5K – –
Northern Trust
10
Northern Trust
Illinois
– -$4K – –
PFS
11
Prospera Financial Services
Texas
– -$4K – –

HEPA Hedge Fund Activity: Q2 2019 in Review

4 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2019, worth a combined $231K — up 133% from $99K a quarter earlier.

Fund positioning in HEPA was balanced in Q2 2019: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $347K. The largest seller was HighTower Advisors, exiting entirely with an estimated $23K sold.

  • 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $231K of Hepion Pharmaceuticals stock for Q2 2019, up 133% quarter-over-quarter.
  • 3 funds opened new Hepion Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of 0 holders.
  • The largest Hepion Pharmaceuticals buyer in Q2 2019 was Virtu Financial, an estimated $347K added.
  • The largest Hepion Pharmaceuticals seller in Q2 2019 was HighTower Advisors, an estimated $23K sold.

Based on aggregated 13F filings for Q2 2019.